Show simple item record

dc.contributor.authorThatcher, Nicken
dc.contributor.authorBlackledge, Gen
dc.contributor.authorCrowther, Dereken
dc.date.accessioned2010-07-21T14:44:36Z
dc.date.available2010-07-21T14:44:36Z
dc.date.issued1980-09-15
dc.identifier.citationAdvanced recurrent squamous cell carcinoma of the head and neck. Results of a chemotherapeutic regimen with adriamycin, bleomycin, 5-fluorouracil, methotrextate, and vitamin A. 1980, 46 (6):1324-8 Canceren
dc.identifier.issn0008-543X
dc.identifier.pmid6158369
dc.identifier.urihttp://hdl.handle.net/10541/108070
dc.description.abstractTwenty-five patients with advanced squamous cell carcinoma of the head and neck were entered into this study. All patients had previously been irradiated and the majority had also undergone surgery for recurrent tumor. A low-dose regimen consisting of adriamycin, bleomycin, 5-fluorouracil, methotrexate, and vitamin A was prescribed, the median number of courses was four and a total of 95 were administered. Ten patients (40%) achieved objective responses (7 partial, 3 complete). The median duration of response was 14 weeks (range, nine to 60 weeks) with a median survival time of 38.5 weeks (range, eight to 72 weeks). The nonresponding patient group's survival time was significantly reduced (P = 0.002; median, 12 weeks; range, three to 40 weeks). The treatment was given on an outpatient basis and no serious hematologic toxic reactions were encountered. Mucositis was uncommon. This regimen produced an acceptable response rate without serious side-effects. The use of Vitamin A may have helped to prevent further impairment of the patient's nutritional status by ameliorating drug-induced mucositis.
dc.language.isoenen
dc.subjectHead and Neck Canceren
dc.subjectCancer Recurrenceen
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAntineoplastic Agents
dc.subject.meshBleomycin
dc.subject.meshCarcinoma, Squamous Cell
dc.subject.meshDoxorubicin
dc.subject.meshDrug Administration Schedule
dc.subject.meshDrug Synergism
dc.subject.meshDrug Therapy, Combination
dc.subject.meshFemale
dc.subject.meshFluorouracil
dc.subject.meshHead and Neck Neoplasms
dc.subject.meshHumans
dc.subject.meshMale
dc.subject.meshMethotrexate
dc.subject.meshMiddle Aged
dc.subject.meshNeoplasm Recurrence, Local
dc.subject.meshPrognosis
dc.subject.meshVitamin A
dc.titleAdvanced recurrent squamous cell carcinoma of the head and neck. Results of a chemotherapeutic regimen with adriamycin, bleomycin, 5-fluorouracil, methotrextate, and vitamin A.en
dc.typeArticleen
dc.identifier.journalCanceren
html.description.abstractTwenty-five patients with advanced squamous cell carcinoma of the head and neck were entered into this study. All patients had previously been irradiated and the majority had also undergone surgery for recurrent tumor. A low-dose regimen consisting of adriamycin, bleomycin, 5-fluorouracil, methotrexate, and vitamin A was prescribed, the median number of courses was four and a total of 95 were administered. Ten patients (40%) achieved objective responses (7 partial, 3 complete). The median duration of response was 14 weeks (range, nine to 60 weeks) with a median survival time of 38.5 weeks (range, eight to 72 weeks). The nonresponding patient group's survival time was significantly reduced (P = 0.002; median, 12 weeks; range, three to 40 weeks). The treatment was given on an outpatient basis and no serious hematologic toxic reactions were encountered. Mucositis was uncommon. This regimen produced an acceptable response rate without serious side-effects. The use of Vitamin A may have helped to prevent further impairment of the patient's nutritional status by ameliorating drug-induced mucositis.


This item appears in the following Collection(s)

Show simple item record